NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $18.96 +0.16 (+0.82%) As of 12:14 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zai Lab Stock (NASDAQ:ZLAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zai Lab alerts:Sign Up Key Stats Today's Range$18.38▼$18.9550-Day Range$17.47▼$25.2552-Week Range$15.96▼$44.34Volume118,799 shsAverage Volume768,636 shsMarket Capitalization$2.15 billionP/E RatioN/ADividend YieldN/APrice Target$45.83Consensus RatingModerate Buy Company Overview Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management. The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies. In collaboration with global partners, Zai Lab has also brought Byooviz (ranibizumab-nuna), a biosimilar to Novartis’s Lucentis, to patients in China suffering from retinal vascular disorders. These flagship products are supported by a commercial infrastructure that spans sales, medical affairs and market access functions. Zai Lab’s development pipeline extends across oncology, autoimmune and inflammatory diseases, neuroscience and infectious diseases. Key clinical programs include targeted therapies for solid tumors, antibody-drug conjugates licensed from international collaborators, and novel small molecules in preclinical stages. The company maintains licensing and development partnerships with leading global biopharma organizations to advance candidates in multiple geographies. Since its founding in 2014, Zai Lab has grown into a fully integrated biopharmaceutical enterprise. Guided by an experienced leadership team with deep industry backgrounds, the company is committed to expanding its product offerings and geographic reach. Zai Lab continues to invest in innovation and global collaboration to address unmet medical needs and bring new therapies to patients worldwide.AI Generated. May Contain Errors. Read More Zai Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreZLAB MarketRank™: Zai Lab scored higher than 79% of companies evaluated by MarketBeat, and ranked 138th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingZai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialZai Lab has a consensus price target of $45.83, representing about 141.7% upside from its current price of $18.96.Amount of Analyst CoverageZai Lab has only been the subject of 4 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.22) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.13% of the float of Zai Lab has been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 5.14.Change versus previous monthShort interest in Zai Lab has recently decreased by 18.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.14 News SentimentZai Lab has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zai Lab this week, compared to 3 articles on an average week.Search Interest3 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold 5,811.91% more of their company's stock than they have bought. Specifically, they have bought $32,733.00 in company stock and sold $1,935,147.00 in company stock.Percentage Held by Insiders4.88% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLAB Stock News HeadlinesZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 21 at 2:15 AM | americanbankingnews.comYing Du Sells 50,000 Shares of Zai Lab (NASDAQ:ZLAB) StockMay 17, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 21 at 1:00 AM | InvestorPlace (Ad)Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab (NASDAQ:ZLAB) Downgraded by Wall Street Zen to SellMay 16, 2026 | americanbankingnews.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 11, 2026 | finance.yahoo.comSee More Headlines ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $17.64 at the beginning of the year. Since then, ZLAB stock has increased by 7.5% and is now trading at $18.96. How were Zai Lab's earnings last quarter? Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) posted its earnings results on Wednesday, April, 1st. The company reported ($0.50) EPS for the quarter. The firm earned $99.61 million during the quarter. Zai Lab had a negative net margin of 39.29% and a negative trailing twelve-month return on equity of 24.32%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $142 million in an IPO on Wednesday, September 20th 2017. The company issued 8,333,333 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD). Company Calendar Last Earnings4/01/2026Today5/21/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ZLAB's financial health is in the Green zone, according to TradeSmith. ZLAB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZLAB CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees1,784Year Founded2014Price Target and Rating Average Price Target for Zai Lab$45.83 High Price Target$75.00 Low Price Target$32.00 Potential Upside/Downside+142.9%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$175.54 million Net Margins-39.29% Pretax Margin-39.62% Return on Equity-24.32% Return on Assets-15.52% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.19 Sales & Book Value Annual Sales$460.16 million Price / Sales4.65 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book3.23Miscellaneous Outstanding Shares113,410,000Free Float107,878,000Market Cap$2.14 billion OptionableOptionable Beta0.85 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ZLAB) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
